Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$19.95 - $31.0 $856,194 - $1.33 Million
-42,917 Reduced 77.26%
12,635 $364,000
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $769,644 - $1.39 Million
22,419 Added 67.66%
55,552 $3.18 Million
Q1 2023

May 15, 2023

BUY
$26.01 - $48.69 $7,334 - $13,730
282 Added 0.86%
33,133 $1.25 Million
Q4 2022

Feb 14, 2023

SELL
$24.14 - $30.37 $4.12 Million - $5.19 Million
-170,757 Reduced 83.87%
32,851 $879,000
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $1.39 Million - $2.08 Million
62,429 Added 44.22%
203,608 $5.76 Million
Q2 2022

Aug 15, 2022

BUY
$19.74 - $43.01 $2.47 Million - $5.37 Million
124,934 Added 769.06%
141,179 $3.06 Million
Q1 2022

May 16, 2022

SELL
$36.25 - $52.02 $853,651 - $1.23 Million
-23,549 Reduced 59.18%
16,245 $652,000
Q4 2021

Feb 14, 2022

BUY
$43.27 - $65.72 $1.72 Million - $2.62 Million
39,794 New
39,794 $1.89 Million
Q3 2021

Nov 15, 2021

SELL
$53.61 - $67.5 $1.29 Million - $1.62 Million
-23,978 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$45.13 - $64.99 $246,409 - $354,845
5,460 Added 29.48%
23,978 $1.38 Million
Q1 2021

May 17, 2021

SELL
$29.77 - $84.85 $484,447 - $1.38 Million
-16,273 Reduced 46.77%
18,518 $1.17 Million
Q4 2020

Feb 16, 2021

BUY
$25.66 - $34.55 $892,737 - $1.2 Million
34,791 New
34,791 $1.17 Million
Q2 2020

Aug 14, 2020

SELL
$12.65 - $29.57 $396,931 - $927,847
-31,378 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$10.84 - $20.85 $340,137 - $654,231
31,378 New
31,378 $461,000
Q4 2019

Feb 14, 2020

SELL
$13.02 - $19.5 $435,024 - $651,534
-33,412 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$17.46 - $29.05 $324,546 - $539,981
-18,588 Reduced 35.75%
33,412 $605,000
Q2 2019

Aug 15, 2019

BUY
$18.0 - $19.82 $936,000 - $1.03 Million
52,000 New
52,000 $1.03 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.31B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.